Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

Macrophages promote both injury and repair after myocardial infarction, but discriminating
functions within mixed populations remains challenging. Here we used fate mapping …

Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Background Cardiovascular morbidity and mortality are higher among patients with type 2
diabetes, particularly those with concomitant cardiovascular diseases, than in most other …

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide
reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …